As genetic activation of NRF2 results in resistance to all current anti-cancer therapies, we were interested in investigating how aberrant activation of NRF2 may impact the clinical response to the new class of KRASG12C inhibitor drugs. The gene discussed is NFE2L2; the disease is cancer.